Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Drugs: A Cohort Study.
Rishi J DesaiSara DejeneYinzhu JinJun LiuSeoyoung C KimPublished in: ACR open rheumatology (2020)
Initiation of abatacept was associated with a lower risk of incident DM in patients with RA compared with infliximab or adalimumab.